Sarcoidosis Market Report 2026

The sarcoidosis market size has grown rapidly in recent years. It will grow from $34.37 billion in 2025 to $39.72 billion in 2026 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to long-standing reliance on corticosteroids as first-line therapy, increasing diagnosis of pulmonary sarcoidosis, growing awareness among pulmonologists and rheumatologists, gradual improvement in diagnostic imaging techniques, limited availability of approved targeted therapies.

The sarcoidosis market size is expected to see rapid growth in the next few years. It will grow to $69.92 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to development of novel biologics and immunomodulators, increasing focus on steroid-sparing treatment options, rising prevalence of chronic and multi-organ sarcoidosis, expansion of clinical research in rare inflammatory diseases, improving patient access to specialty care centers. Major trends in the forecast period include increasing off-label use of biologics for refractory sarcoidosis, growing focus on pulmonary sarcoidosis management, rising adoption of corticosteroid-sparing treatment regimens, increased use of imaging and biomarker-based disease monitoring, expanding clinical trials for novel anti-inflammatory therapies.

The growing emphasis on personalized medicine is expected to drive the growth of the sarcoidosis market in the coming years. Personalized medicine is an advanced medical approach that customizes therapeutic strategies for individual patients based on their genetic profile, biomarkers, environmental factors, and lifestyle, enabling more precise, effective, and targeted interventions. The demand for personalized medicine is increasing because it allows treatments to be tailored to an individual’s genetic makeup and biological profile, improving efficacy while reducing side effects. In sarcoidosis, personalized medicine uses genetic, biomarker, and clinical profiling to optimize treatment, enhancing targeted therapy and addressing disease heterogeneity and individual patient responses. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, up from 6 approvals in 2022. Therefore, the increasing focus on personalized medicine is supporting growth in the sarcoidosis market.

Leading companies in the sarcoidosis market are focusing on innovative therapies, such as anti-TNFα monoclonal antibody treatments, to introduce novel biologic options that address critical unmet needs in managing inflammatory diseases. Anti-tumor necrosis factor-alpha (anti-TNFα) monoclonal antibody therapy is a targeted immunotherapy that inhibits TNFα, a pro-inflammatory cytokine, reducing inflammation and controlling autoimmune conditions. For instance, in November 2023, Xentria, Inc., a US-based clinical-stage biotherapeutics company, achieved a milestone as its lead candidate, XTMAB-16, received Orphan Drug Designation from the European Medicines Agency (EMA). At the same time, the company began a global clinical study for pulmonary sarcoidosis, enrolling the first patient. XTMAB-16, a monoclonal antibody targeting TNFα, is being evaluated for its ability to modulate inflammatory pathways in pulmonary sarcoidosis, offering a targeted alternative to corticosteroid-based therapies. This regulatory recognition and clinical progress underscore the growing focus on innovative biologics for rare diseases and highlight Xentria’s commitment to providing transformative treatment options for unmet medical needs.

In June 2023, Xentria Inc., a US-based biotherapeutics company, partnered with Meitheal Pharmaceuticals Inc. to accelerate the development and commercialization of XTMAB-16. Under this collaboration, Meitheal Pharmaceuticals obtained exclusive commercialization rights for XTMAB-16 in North America, while Xentria continues to lead clinical development and regulatory efforts. The partnership aims to expand market access and improve treatment options for patients with pulmonary sarcoidosis by combining Xentria’s expertise in biologics with Meitheal’s strong commercialization capabilities. Meitheal Pharmaceuticals, Inc., based in the US, specializes in developing and commercializing generic injectables, fertility treatments, biologics, and branded products.

Major companies operating in the sarcoidosis market are Pfizer Inc, F Hoffmann La Roche AG, Merck And Co Inc, AbbVie Inc, Novartis AG, Bristol Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly And Company, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc, UCB Pharma, Sun Pharmaceutical Industries Ltd, Cipla Ltd, Lupin Limited, Mallinckrodt Pharmaceuticals, Xentria Inc, Molecure SA, Relief Therapeutics Holding AG, Sanofi SA, Amgen Inc, Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd.

Europe was the largest region in the sarcoidosis market in 2025. The regions covered in the sarcoidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sarcoidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the sarcoidosis market by increasing costs of imported biologics, active pharmaceutical ingredients, and diagnostic equipment used in disease management and monitoring. These effects are most pronounced in advanced treatment segments and hospital-based care, particularly in north america and europe where biologic adoption is higher. Tariffs are encouraging regional drug manufacturing, localized supply chains, and domestic production of diagnostics, which may improve long-term treatment accessibility and market stability.

The sarcoidosis market research report is one of a series of new reports that provides sarcoidosis market statistics, including sarcoidosis industry global market size, regional shares, competitors with a sarcoidosis market share, detailed sarcoidosis market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoidosis industry. This sarcoidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sarcoidosis is a complex inflammatory disease marked by the formation of granulomas, which are small clusters of immune cells that can develop in various organs, most commonly the lungs and lymph nodes. These granulomas can lead to organ dysfunction, respiratory problems, or systemic complications. The exact cause of sarcoidosis remains unknown, but it is thought to involve an abnormal immune response to environmental or genetic factors.

The main types of sarcoidosis include pulmonary sarcoidosis, ocular sarcoidosis, neurosarcoidosis, cardiac sarcoidosis, musculoskeletal sarcoidosis, cutaneous sarcoidosis, renal sarcoidosis, hepatic sarcoidosis, and sarcoidosis affecting the spleen and bone marrow. Pulmonary sarcoidosis is a chronic inflammatory condition in which granulomas form in the lungs, causing respiratory symptoms such as cough and shortness of breath, and potentially leading to lung fibrosis if untreated. Diagnosis involves imaging techniques, biopsies, and blood tests, while treatments include corticosteroids, immunosuppressive agents, biologics, and anti-malarial drugs. These treatments can be administered orally, parenterally, or via other routes and are utilized in hospitals, clinics, surgical centers, diagnostic centers, and other healthcare settings.

The sarcoidosis market includes revenues earned by entities by providing services such as diagnostic tests, laboratory testing, gene therapies, disease management services, clinical trials, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcoidosis market also includes sales of corticosteroids, immunosuppressive agents, and antimalarial drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.